The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients

Parkinsonism and Related Disorders

Volumn 15, Issue 9, 2009, Pages 655-659

  Go, Criscely L ^a   Rosales, Raymond L ^a   Caraos, Rico J ^b   Fernandez, Hubert H ^c  

^a UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^b National Center for Mental Health   (Philippines)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Movement disorder; Neuroleptic; Schizophrenia; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLIBENCLAMIDE; HALOPERIDOL; LEVOMEPROMAZINE; METFORMIN; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CERVICAL DYSTONIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FILIPINO; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX RATIO; SUBSTANCE ABUSE; TARDIVE DYSKINESIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PHILIPPINES; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 70350281579     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2009.02.015     Document Type: Article

References (30)

1. Fernandez H., and Friedman J.H. Classification and treatment of tardive syndromes. Neurologist 9 (2003) 16-27
2. Chong S.A., and Sachdev P. The epidemiology of tardive dyskinesia. In: Sethi K. (Ed). Drug induced movement disorders Ch. 3 (2004), Marcel Dekker, New York 33-37
3. Chong S.A., Mahendran R., Machin D., Chua H.C., Parker G., and Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol 22 (2002) 26-30
4. Woerner M.G., Alvir M.J., Saltz B.L., Liebermann J.A., and Kane J.M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155 (1998) 1521-1528
5. Jeste D.V. Tardive dyskinesia in older patients. J Clin Psychiatry 61 Suppl 14 (2000) 27-32
6. Chiu H.F., Wing Y.K., and Kwong P.K. Prevalence of tardive dyskinesia in samples of elderly people in Hong Kong. Acta Psychiatr Scand 87 (1993) 266-268
7. Krueger R.B., and Sackheim H.A. Electroconvulsive therapy and schizophrenia. In: Hirsh S.R., and Weinberger D.R. (Eds). Schizophrenia (1995), Blackwell Science, England 305-545
8. Fahn, S. A comprehensive review of movement disorders for the clinical practitioner. the tardive syndromes: phenomenology, concepts on pathophysiology, and treatment and other neuroleptic-induced syndromes. The Movement Disorders 14th Course. Aspen, CO. 2004. p. 191-247.
9. Janno S., and Holi M. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenic in patients. Am J Psychiatry 161 (2004) 160-163
10. Schooler N.R., and Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39 (1982) 486-487
11. Jeste D.V., Lacro J.P., Palmer B., Rockwell E., Harris J., and Caligiuri M.P. Incidence of tardive dyskinesia in early stages of low dose treatment with typical neuroleptics in older patients. Am J Psychiatry 156 (1999) 309-311
12. Yassa R., and Jeste D.V. Gender differences in tardive dyskinesia: a critical review of literature. Schizophr Bull 18 (1992) 701-710
13. Lehman A.F., and Steinwachs D.M. At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) Treatment recommendations. Schizophr Bull 24 (1998) 1-10
14. Yassa R., Nair N.V.P., and Jeste D.V. Neuroleptic induced movement disorders. a comprehensive survey (1997), Cambridge University Press p. 257-9
15. Ananda K., Pandurangi, and Yekeen A. Tardive dyskinesia in non-western countries: A review. Euro Arch Psychiatry Clin Neurosci 246 (1995) 47-52
16. Tan C.H., and Tay L.K. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aus NZ J Psychiatry 25 (1991) 119-122
17. Osman A., Marghalani M., Turkistani I.Y., Al-Swaf M., and Bin Sadiq B. Neuroleptic-induced tardive dyskinesia among Arab psychotic patients. East Mediterr Health J 13 (2007) 625-632
18. Lerner V., Libov I., Kaptsan A., Miodownik C., Dwolatzky T., and Levine J. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci 4 (2007) 20-28
19. Doongaji D.R., Jeste D.V., Jape N.M., Sheth A.S., Apte J.S., Vahia V.N., et al. Tardive dyskinesia in India: a prevalence study. J Clin Psychopharmacol 2 (1982) 341-344
20. Wegner J., and Kane J. Follow-up study on the reversibility of tardive dyskinesia. Am J Psychiatry 139 (1982) 368-369
21. Klawans H., Tanner D., and Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol 7 (1984) 153-159
22. Casey D., Povlsen U., and Meidahl B. Neuroleptic-induced tardive dyskinesia and parkinsonism: change during several years of continuing treatment. Psychopharmacol Bull 22 (1986) 250-253
23. Yagi G., and Itoh H. A 10-year follow-up study of tardive dyskinesia with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med 34 (1985) 211-219
24. Soares-Weiser K., and Fernandez H.H. Tardive dyskinesia. Semin Neurol 27 (2007) 159-169
25. Muscettola G. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 87 (1997) 29-36
26. Seeman M.V. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 161 (2004) 1324-1333
27. Fernandez H., Krupp B., and Friedman J. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 56 (2001) 805-807
28. Chong S., Tan E.C., and Tan C.H. Mythily. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 28 (2003) 185-189
29. Fernandez H.H., McCown K., Romrell J., Trieschmann M.E., Friedman J.H., Jacobson C.E., et al. New-onset diabetes mellitus among parkinsonian patients treated with long-term quetiapine. Drug Target Insights 3 (2008) 27-29
30. Fernandez H.H., Friedman J.H., Lansang M.C., Factor S.A., Molho E.S., and Coskun D.J. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord 10 (2004) 439-441